NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President & Chief Executive Officer, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020, at 2:00 PM ET.
The Company will present virtually and provide updates about recent developments and key highlights including progress with BVA-100 as well as be available to participate in one-on-one meetings.Event: H.C. Wainwright 22nd Annual Global Investment ConferenceDate: Tuesday, September 15th, 2020Presentation: 2:00 PM ET – 2:20 PM ETRegister here:
https://www.meetmax.com/sched/event_61861/investor_reg_new.html?attendee_role_id=INVESTORHC Wainwright will take place on September 14th through the 16th.About Daxor CorporationDaxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information, please visit our website at Daxor.com.Forward-Looking StatementsCertain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
[email protected]
Bay Street News
